BeOne Medicines Ltd. (ONC) is the 15th largest of 300 Pharmaceuticals companies by market capitalisation, at 40.16 Bn, behind Teva Pharmaceutical Industries Ltd at 42.99 Bn. It trades on a P/E of 61.25, 210% above the peer median of 19.79. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 665.89 Bn | 31.65 | 6.80 | 645.13 Bn |
| 2 | ABBV | AbbVie Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 455.43 Bn | 72.11 | 7.07 | 448.86 Bn |
| 3 | MRK | Merck & Co., Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 373.22 Bn | 117.77 | 5.61 | 366.08 Bn |
| 4 | NVS | Novartis Ag | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 310.92 Bn | 13.82 | 4.52 | 303.23 Bn |
| 5 | PFE | Pfizer Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 163.33 Bn | 37.39 | 2.56 | 151.63 Bn |
| 6 | SNY | Sanofi | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 54.04 Bn | 11.59 | 1.01 | 46.66 Bn |
| 7 | RVMD | Revolution Medicines, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 44.05 Bn | -24.91 | — | 44.05 Bn |
| 8 | ONC | BeOne Medicines Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 40.16 Bn | 61.25 | 6.55 | 35.06 Bn |
| 9 | INCY | Incyte Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 25.60 Bn | 15.88 | 4.40 | 21.07 Bn |
| 10 | UTHR | UNITED THERAPEUTICS Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 20.92 Bn | 15.96 | 6.63 | 18.26 Bn |
| 11 | NBIX | Neurocrine Biosciences Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.83 Bn | 22.43 | 4.69 | 15.44 Bn |
| 12 | JAZZ | Jazz Pharmaceuticals plc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.67 Bn | 16.66 | 3.41 | 14.05 Bn |
| 13 | EXEL | Exelixis, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 14.83 Bn | 17.23 | 6.09 | 13.99 Bn |
| 14 | CORT | Corcept Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 11.62 Bn | 214.44 | 13.99 | 11.31 Bn |
| 15 | KYMR | Kymera Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 11.48 Bn | -38.33 | 109.36 | 10.79 Bn |
| 16 | AXSM | Axsome Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.75 Bn | -69.92 | 13.84 | 10.43 Bn |
| 17 | GPCR | Structure Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.26 Bn | -54.52 | — | 10.26 Bn |
| 18 | NUVL | Nuvalent, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.75 Bn | -27.07 | — | 9.75 Bn |
| 19 | CYTK | Cytokinetics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.59 Bn | -13.08 | 141.79 | 8.43 Bn |
| 20 | CRNX | Crinetics Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 8.99 Bn | -17.90 | 213.22 | 8.99 Bn |
| 21 | ALKS | Alkermes plc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 7.77 Bn | 117.51 | 4.66 | 7.12 Bn |
| 22 | BLTE | Belite Bio, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.21 Bn | -80.67 | — | 6.21 Bn |
| 23 | TVTX | Travere Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.15 Bn | -141.45 | 10.40 | 6.15 Bn |
| 24 | LQDA | Liquidia Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.12 Bn | 44.17 | 13.57 | 5.84 Bn |
| 25 | AMRN | Amarin Corp Plc\Uk | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 5.70 Bn | -210.19 | 30.61 | 5.39 Bn |
| 26 | ACAD | Acadia Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.78 Bn | 12.57 | 4.20 | 3.83 Bn |
| 27 | EWTX | Edgewise Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.52 Bn | -22.94 | — | 4.52 Bn |
| 28 | DFTX | Definium Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.19 Bn | -11.84 | — | 4.19 Bn |
| 29 | INDV | Indivior Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.16 Bn | 11.71 | 3.12 | 3.93 Bn |
| 30 | MANE | Veradermics, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.97 Bn | -46.05 | — | 3.97 Bn |
| 31 | ELVN | Enliven Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.93 Bn | -46.76 | — | 3.93 Bn |
| 32 | CPRX | CATALYST PHARMACEUTICALS, INC. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | 17.94 | 6.45 | 3.09 Bn |
| 33 | TARS | Tarsus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.64 Bn | -77.48 | 6.00 | 3.19 Bn |
| 34 | OGN | Organon & Co. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.62 Bn | 17.31 | 0.59 | 2.49 Bn |
| 35 | NAMS | NewAmsterdam Pharma Co N.V. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | -12.00 | 437.28 | 3.11 Bn |
| 36 | TAK | Takeda Pharmaceutical Co Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.65 Bn | 4.62 | 0.06 | -3.14 Bn |
| 37 | TRVI | Trevi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.63 Bn | -62.45 | — | 2.63 Bn |
| 38 | SUPN | Supernus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.54 Bn | -29.87 | 3.23 | 2.17 Bn |
| 39 | HRMY | Harmony Biosciences Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | 13.65 | 2.54 | 1.63 Bn |
| 40 | NUVB | Nuvation Bio Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.35 Bn | -21.77 | 13.86 | 2.35 Bn |
| 41 | MLYS | Mineralys Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.34 Bn | -6.68 | — | 2.34 Bn |
| 42 | PVLA | Palvella Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.22 Bn | -41.87 | — | 1.91 Bn |
| 43 | AUPH | Aurinia Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.11 Bn | 6.70 | 6.76 | 1.66 Bn |
| 44 | ETON | Eton Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | 166.67 | 15.87 | 1.56 Bn |
| 45 | INVA | Innoviva, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.56 Bn | 7.95 | 3.03 | 0.98 Bn |
| 46 | LBRX | Lb Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.47 Bn | -24.26 | — | 1.47 Bn |
| 47 | XERS | Xeris Biopharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -85.08 | 4.35 | 1.34 Bn |
| 48 | HROW | Harrow, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | -42.94 | 5.21 | 1.35 Bn |
| 49 | OPK | Opko Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | -31.99 | 2.06 | 0.91 Bn |
| 50 | KURA | Kura Oncology, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.16 Bn | -4.88 | 15.04 | 1.16 Bn |
| 51 | OLMA | Olema Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.12 Bn | -5.47 | — | 1.12 Bn |
| 52 | PCRX | Pacira BioSciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.05 Bn | 71.49 | 1.40 | 0.80 Bn |
| 53 | LXRX | Lexicon Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.98 Bn | -15.62 | 23.69 | 0.79 Bn |
| 54 | SGP | SpyGlass Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.96 Bn | -48.80 | — | 0.96 Bn |
| 55 | DSGN | Design Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.95 Bn | -11.69 | — | 0.74 Bn |
| 56 | IVA | Inventiva S.A. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.90 Bn | 9.70 | 179.22 | 0.90 Bn |
| 57 | COLL | Collegium Pharmaceutical, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | 16.44 | 0.97 | 0.64 Bn |
| 58 | VSTM | Verastem, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.79 Bn | -6.81 | 8.97 | 0.65 Bn |
| 59 | PHAT | Phathom Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.75 Bn | -7.63 | 3.13 | 0.56 Bn |
| 60 | ZVRA | Zevra Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.74 Bn | 12.66 | 5.42 | 0.52 Bn |
| 61 | AQST | Aquestive Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.68 Bn | -8.67 | 12.54 | 0.68 Bn |
| 62 | GYRE | Gyre Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | -36.08 | 5.58 | 0.61 Bn |
| 63 | CRMD | CorMedix Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.66 Bn | 5.24 | 1.76 | 0.40 Bn |
| 64 | MPLT | MapLight Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.62 Bn | -3.06 | — | 0.62 Bn |
| 65 | EOLS | Evolus, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -17.28 | 1.87 | 0.55 Bn |
| 66 | NVCT | Nuvectis Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -19.50 | — | 0.59 Bn |
| 67 | SPRY | ARS Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.56 Bn | -2.52 | 4.76 | 0.41 Bn |
| 68 | OVID | Ovid Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.55 Bn | -16.00 | 348.63 | 0.43 Bn |
| 69 | XFOR | X4 Pharmaceuticals, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.51 Bn | -5.68 | 32.29 | 0.32 Bn |
| 70 | PALI | Palisade Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.45 Bn | -12.67 | 894.15 | 0.32 Bn |
| 71 | IKT | Inhibikase Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -6.67 | — | 0.28 Bn |
| 72 | VTVT | vTv Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -86.99 | 11.23 | 0.41 Bn |
| 73 | ACHV | Achieve Life Sciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.37 Bn | — | — | 0.37 Bn |
| 74 | VNDA | Vanda Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.18 | 1.50 | 0.15 Bn |
| 75 | EBS | Emergent BioSolutions Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.83 | 0.42 | 0.18 Bn |
| 76 | IMRX | Immuneering Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -5.42 | — | 0.32 Bn |
| 77 | SION | Sionna Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -3.26 | — | 0.32 Bn |
| 78 | TTRX | Turn Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.30 Bn | -38.33 | — | 0.30 Bn |
| 79 | FULC | Fulcrum Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -3.28 | — | 0.29 Bn |
| 80 | ZNTL | Zentalis Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -2.02 | — | 0.28 Bn |
| 81 | AKBA | Akebia Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -8.93 | 1.21 | 0.11 Bn |
| 82 | SIGA | Siga Technologies Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.23 Bn | — | — | 0.07 Bn |
| 83 | NERV | Minerva Neurosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -33.42 | — | 0.22 Bn |
| 84 | TNXP | Tonix Pharmaceuticals Holding Corp. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -1.37 | 7.53 | 0.22 Bn |
| 85 | DERM | Journey Medical Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | -59.60 | 3.20 | 0.19 Bn |
| 86 | ACOG | Alpha Cognition Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -7.38 | 15.13 | 0.16 Bn |
| 87 | SLGL | Sol-Gel Technologies Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -18.72 | 109.36 | 0.15 Bn |
| 88 | MCUJF | Medicure Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -36.51 | 8.32 | 0.19 Bn |
| 89 | CRDL | Cardiol Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -7.14 | — | 0.17 Bn |
| 90 | CELG-RI | Bristol Myers Squibb Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | 0.02 | 0.00 | -10.88 Bn |
| 91 | LONA | LeonaBio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.48 | — | 0.13 Bn |
| 92 | LENZ | LENZ Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -1.39 | 8.36 | 0.18 Bn |
| 93 | MENS | Jyong Biotech Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.17 Bn | -44.35 | — | 0.17 Bn |
| 94 | BMEA | Biomea Fusion, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -2.63 | — | 0.15 Bn |
| 95 | NTHI | Neonc Technologies Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -2.83 | — | 0.13 Bn |
| 96 | VANI | Vivani Medical, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -4.53 | — | 0.10 Bn |
| 97 | AARD | Aardvark Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.12 Bn | -1.74 | — | 0.05 Bn |
| 98 | VRCA | Verrica Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -3.62 | 3.75 | 0.10 Bn |
| 99 | CPIX | Cumberland Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -9.45 | 3.26 | 0.10 Bn |
| 100 | CGTX | Cognition Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -2.56 | — | 0.09 Bn |
| 101 | PTHS | Pelthos Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -0.78 | 1.62 | 0.06 Bn |
| 102 | RGC | Regencell Bioscience Holdings Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | — | — | 0.08 Bn |
| 103 | TENX | Tenax Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.29 | — | 0.08 Bn |
| 104 | MNOV | Medicinova Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -6.72 | 88.45 | 0.08 Bn |
| 105 | PMVP | PMV Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.16 | — | -0.01 Bn |
| 106 | PLRX | Pliant Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -0.74 | — | 0.07 Bn |
| 107 | CING | Cingulate Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -3.08 | — | 0.07 Bn |
| 108 | BOLD | Boundless Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -1.01 | — | 0.06 Bn |
| 109 | VERU | Veru Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 125.20 | — | 0.04 Bn |
| 110 | GOSS | Gossamer Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.32 | 1.03 | 0.00 Bn |
| 111 | KPTI | Karyopharm Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.27 | 0.35 | 0.05 Bn |
| 112 | ANVS | Annovis Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.07 | — | 0.05 Bn |
| 113 | CLNN | Clene Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.41 | 225.73 | 0.05 Bn |
| 114 | APRE | Aprea Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.40 | — | 0.04 Bn |
| 115 | IXHL | Incannex Healthcare Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.84 | — | 0.04 Bn |
| 116 | SCLX | Scilex Holding Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.08 | 1.19 | -0.08 Bn |
| 117 | GRCE | Grace Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.84 | — | 0.04 Bn |
| 118 | ACTU | Actuate Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.65 | — | 0.03 Bn |
| 119 | CPHI | China Pharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -7.61 | 8.70 | 0.03 Bn |
| 120 | UG | United Guardian Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 14.46 | 2.92 | 0.02 Bn |
| 121 | NSRX | Nasus Pharma Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -5.64 | — | 0.03 Bn |
| 122 | CRVO | CervoMed Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.87 | 79.78 | 0.03 Bn |
| 123 | YARW | Yarrow Bioscience, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.23 | 51.20 | 0.00 Bn |
| 124 | BYSI | BeyondSpring Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.04 | — | 0.03 Bn |
| 125 | TXMD | TherapeuticsMD, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -138.89 | 7.86 | 0.02 Bn |
| 126 | AYTU | Aytu Biopharma, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.77 | 0.42 | 0.00 Bn |
| 127 | ALLR | Allarity Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.89 | 916.33 | 0.02 Bn |
| 128 | ATOS | Atossa Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.74 | — | 0.02 Bn |
| 129 | BFRI | Biofrontera Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -4.27 | 0.45 | 0.02 Bn |
| 130 | MIRA | Mira Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.55 | — | 0.01 Bn |
| 131 | TVRD | Tvardi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.66 | — | 0.02 Bn |
| 132 | CTXR | Citius Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.34 | 2.21 | 0.02 Bn |
| 133 | KPRX | Kiora Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.43 | — | 0.02 Bn |
| 134 | INTI | Inhibitor Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -4.72 | — | 0.02 Bn |
| 135 | ANEB | Anebulo Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.37 | — | 0.01 Bn |
| 136 | CALC | CalciMedica, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.36 | -8.91 | -0.01 Bn |
| 137 | CURX | Curanex Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.92 | — | 0.00 Bn |
| 138 | RVPH | Reviva Pharmaceuticals Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.75 | — | 0.01 Bn |
| 139 | ADXN | Addex Therapeutics Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | 0.05 | — | 0.01 Bn |
| 140 | ACXP | Acurx Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.79 | — | 0.01 Bn |
| 141 | TRAW | Traws Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.34 | — | 0.00 Bn |
| 142 | PCSA | Processa Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.42 | — | 0.01 Bn |
| 143 | PULM | Pulmatrix, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.31 | — | 0.01 Bn |
| 144 | TCRT | Alaunos Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.99 | 1,333.38 | 0.00 Bn |
| 145 | CVKD | Cadrenal Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.31 | — | 0.00 Bn |
| 146 | BICX | BioCorRx Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.64 | 6.70 | 0.00 Bn |
| 147 | CASIF | CASI Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.02 | 0.12 | 0.00 Bn |
| 148 | SKVI | Skinvisible, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -2.25 | 116.18 | 0.00 Bn |
| 149 | OGEN | Oragenics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.22 | — | 0.00 Bn |
| 150 | UPC | Universe Pharmaceuticals INC | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -1,490.23 Bn |
| 151 | CANF | Can-Fite BioPharma Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.21 | 5.02 | -0.01 Bn |
| 152 | ENSC | Ensysce Biosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 153 | MTNB | Matinas BioPharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.15 | — | 0.00 Bn |
| 154 | SPRC | SciSparc Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.05 | 0.77 | 0.00 Bn |
| 155 | NCEL | NewcelX Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.06 | — | 0.00 Bn |
| 156 | JAGX | Jaguar Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.01 | 0.02 | -0.01 Bn |
| 157 | GLMD | Galmed Pharmaceuticals Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -0.01 Bn |
| 158 | CDT | CDT Equity Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.01 | — | 0.00 Bn |
| 159 | GCAN | Trafalgar International, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.77 | — | 0.00 Bn |
| 160 | SXTC | China SXT Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | 0.03 | -0.03 Bn |
| 161 | CMND | Clearmind Medicine Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | -0.01 Bn |
| 162 | AMGN | Amgen Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 236.84 Bn | 27.09 | 6.22 | 222.85 Bn |
| 163 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 187.61 Bn | -64.81 | 6.16 | 184.43 Bn |
| 164 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 140.22 Bn | 31.83 | 11.14 | 132.37 Bn |
| 165 | REGN | Regeneron Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 86.04 Bn | 19.88 | 5.54 | 78.05 Bn |
| 166 | ARGX | Argenx Se | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 63.70 Bn | 37.14 | 12.19 | 58.52 Bn |
| 167 | MRNA | Moderna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 57.56 Bn | -18.27 | 25.83 | 52.42 Bn |
| 168 | TEVA | Teva Pharmaceutical Industries Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 42.99 Bn | 61.77 | 2.48 | 39.33 Bn |
| 169 | ALNY | Alnylam Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 35.63 Bn | 45.99 | 7.42 | 32.32 Bn |
| 170 | ALC | Alcon Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 34.97 Bn | 29.36 | 3.25 | 33.51 Bn |
| 171 | BIIB | Biogen Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.64 Bn | 39.10 | 3.25 | 31.35 Bn |
| 172 | GEHC | GE HealthCare Technologies Inc. | secondary | H-08 | Medical Devices and Diagnostics | HG-02 | 31.29 Bn | 15.26 | 1.47 | 29.19 Bn |
| 173 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 27.73 Bn | -31.67 | 24.37 | 26.57 Bn |
| 174 | BNTX | BioNTech SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 25.27 Bn | -14.83 | 8.17 | 11.62 Bn |
| 175 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 24.89 Bn | -16.77 | 2,278.53 | 24.89 Bn |
| 176 | VTRS | Viatris Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 19.75 Bn | -48.08 | 1.34 | 18.86 Bn |
| 177 | ZBH | Zimmer Biomet Holdings, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 18.91 Bn | 22.32 | 2.22 | 18.50 Bn |
| 178 | ASND | Ascendis Pharma A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.26 Bn | -513.41 | 13.32 | 15.32 Bn |
| 179 | MDGL | Madrigal Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.93 Bn | -49.93 | 12.41 | 15.09 Bn |
| 180 | BBIO | BridgeBio Pharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.58 Bn | -21.07 | 20.45 | 13.86 Bn |
| 181 | BWXT | BWX Technologies, Inc. | secondary | I-39 | Clean Energy Equipment | IG-10 | 14.56 Bn | 40.89 | 4.14 | 13.96 Bn |
| 182 | SMMT | Summit Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.49 Bn | — | — | 12.80 Bn |
| 183 | HALO | Halozyme Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.89 Bn | 31.17 | 7.75 | 12.66 Bn |
| 184 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.85 Bn | 176.03 | 3.77 | 11.97 Bn |
| 185 | ARWR | Arrowhead Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.17 Bn | -44.72 | 18.18 | 10.57 Bn |
| 186 | GMED | Globus Medical Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.54 Bn | 19.69 | 3.35 | 9.95 Bn |
| 187 | GKOS | GLAUKOS Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 10.38 Bn | -65.92 | 16.94 | 10.27 Bn |
| 188 | PRAX | Praxis Precision Medicines, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.28 Bn | -26.96 | — | 9.52 Bn |
| 189 | APGE | Apogee Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 190 | RDY | Dr Reddys Laboratories Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 9.97 Bn | 790.08 | 2.72 | 9.80 Bn |
| 191 | IONS | Ionis Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.68 Bn | -45.60 | 11.07 | 7.62 Bn |
| 192 | PTGX | Protagonist Therapeutics, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.64 Bn | 87.35 | 34.20 | 9.64 Bn |
| 193 | PCVX | Vaxcyte, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.91 Bn | -8.43 | — | 8.91 Bn |
| 194 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.59 Bn | -8.66 | 51.84 | 8.24 Bn |
| 195 | IMVT | Immunovant, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.05 Bn | -14.95 | — | 8.05 Bn |
| 196 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.99 Bn | 18.09 | 9.99 | 7.31 Bn |
| 197 | ABVX | Abivax S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.91 Bn | -21.25 | — | 7.91 Bn |
| 198 | SYRE | Spyre Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.43 Bn | -41.53 | — | 7.43 Bn |
| 199 | SRRK | Scholar Rock Holding Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.23 Bn | -17.91 | — | 7.23 Bn |
| 200 | RYTM | Rhythm Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.04 Bn | -33.50 | 29.36 | 6.71 Bn |
| 201 | BLRX | BioLineRx Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.68 Bn | -745.97 | 4,799.49 | 6.68 Bn |
| 202 | CGON | CG Oncology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.55 Bn | -29.21 | 1,051.38 | 6.55 Bn |
| 203 | BLCO | Bausch & Lomb Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 6.43 Bn | -39.48 | 1.21 | 6.06 Bn |
| 204 | MIRM | Mirum Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.41 Bn | -7.45 | 10.36 | 5.97 Bn |
| 205 | KNSA | Kiniksa Pharmaceuticals International, plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.14 Bn | 76.16 | 7.31 | 5.62 Bn |
| 206 | COGT | Cogent Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.97 Bn | -16.14 | — | 5.97 Bn |
| 207 | XENE | Xenon Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.94 Bn | -16.37 | — | 5.94 Bn |
| 208 | ORKA | Oruka Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.88 Bn | — | — | 4.15 Bn |
| 209 | DBVT | DBV Technologies S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.81 Bn | -33.03 | 1,158.34 | 5.64 Bn |
| 210 | PTCT | Ptc Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.80 Bn | 15.17 | 5.75 | 3.57 Bn |
| 211 | LGND | Ligand Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.75 Bn | 29.14 | 19.78 | 4.39 Bn |
| 212 | AMRX | Amneal Pharmaceuticals, Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 5.63 Bn | 26.13 | 1.80 | 5.50 Bn |
| 213 | GRFS | Grifols SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.31 Bn | 20.91 | 0.32 | 4.15 Bn |
| 214 | CELC | Celcuity Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.26 Bn | -24.01 | — | 5.26 Bn |
| 215 | ERAS | Erasca, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.08 Bn | -17.69 | — | 5.08 Bn |
| 216 | RADX | Radiopharm Theranostics Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.36 Bn | -59.20 | 20,980.03 | 4.36 Bn |
| 217 | DNLI | Denali Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.17 Bn | -8.15 | 1,156.51 | 4.17 Bn |
| 218 | DNTH | Dianthus Therapeutics, Inc. /DE/ | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.06 Bn | — | — | 3.66 Bn |
| 219 | DYN | Dyne Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.05 Bn | -7.85 | — | 4.05 Bn |
| 220 | TLX | Telix Pharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.03 Bn | — | — | 3.74 Bn |
| 221 | IOVA | Iovance Biotherapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 4.00 Bn | -19.13 | 12.30 | 3.70 Bn |
| 222 | VKTX | Viking Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.99 Bn | -7.46 | — | 3.99 Bn |
| 223 | RLAY | Relay Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.84 Bn | -13.42 | 370.62 | 3.84 Bn |
| 224 | AMLX | Amylyx Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.76 Bn | -30.98 | — | 3.76 Bn |
| 225 | RCUS | Arcus Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.73 Bn | -8.11 | 31.88 | 3.03 Bn |
| 226 | IDYA | IDEAYA Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.66 Bn | -16.64 | 15.65 | 2.84 Bn |
| 227 | ABCL | AbCellera Biologics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.49 Bn | -21.20 | 52.76 | 3.49 Bn |
| 228 | TNGX | Tango Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.38 Bn | -32.99 | 62.75 | 2.36 Bn |
| 229 | ARQT | Arcutis Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.11 Bn | 109.08 | 6.70 | 2.87 Bn |
| 230 | IRON | Disc Medicine, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.07 Bn | -15.22 | — | 3.07 Bn |
| 231 | CLDX | Celldex Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.06 Bn | -9.95 | 19,361.47 | 3.06 Bn |
| 232 | IMNM | Immunome Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.05 Bn | -11.29 | 593.06 | 2.53 Bn |
| 233 | MBX | MBX Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.93 Bn | -28.12 | — | 2.93 Bn |
| 234 | ZLAB | Zai Lab Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.90 Bn | -15.40 | 6.45 | 2.19 Bn |
| 235 | NRIX | Nurix Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.85 Bn | -8.35 | 77.53 | 2.41 Bn |
| 236 | SLS | SELLAS Life Sciences Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.64 Bn | -81.45 | — | 2.64 Bn |
| 237 | VERA | Vera Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.56 Bn | -6.40 | — | 2.56 Bn |
| 238 | AXGN | Axogen, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 2.54 Bn | -171.72 | 10.11 | 2.43 Bn |
| 239 | BCRX | Biocryst Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.53 Bn | -6.57 | 4.72 | 2.17 Bn |
| 240 | CURLF | Curaleaf Holdings, Inc. | secondary | S-09 | Tobacco and Cannabis | SG-04 | 2.52 Bn | -21.25 | 1.92 | 2.42 Bn |
| 241 | BHC | Bausch Health Companies Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 2.49 Bn | -2.28 | 0.23 | 0.66 Bn |
| 242 | NKTR | Nektar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.44 Bn | -20.56 | 44.76 | 1.76 Bn |
| 243 | HCM | HUTCHMED (China) Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.43 Bn | 3.27 | 3.41 | 2.43 Bn |
| 244 | OCUL | Ocular Therapeutix, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | -7.97 | 46.37 | 2.41 Bn |
| 245 | VRDN | Viridian Therapeutics, Inc.\DE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.40 Bn | -6.00 | 33.72 | 2.40 Bn |
| 246 | BHVN | Biohaven Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.35 Bn | -4.00 | — | 2.08 Bn |
| 247 | SRPT | Sarepta Therapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.33 Bn | -17.03 | 1.18 | 1.54 Bn |
| 248 | XTLB | Xtl Biopharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.25 Bn | -3,010.83 | — | 2.25 Bn |
| 249 | RAPP | Rapport Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | -16.28 | 111.66 | 2.23 Bn |
| 250 | KOD | Kodiak Sciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.23 Bn | -9.22 | — | 2.23 Bn |
| 251 | URGN | UroGen Pharma Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.21 Bn | -35.52 | 11.72 | 2.10 Bn |
| 252 | FMS | Fresenius Medical Care AG | secondary | H-14 | Healthcare Providers | HG-04 | 2.21 Bn | 1.85 | 0.08 | 0.38 Bn |
| 253 | GMAB | Genmab A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | 0.17 | 0.34 | 0.69 Bn |
| 254 | ADMA | Adma Biologics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.17 Bn | 13.05 | 4.24 | 2.03 Bn |
| 255 | ZYME | Zymeworks Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.15 Bn | -14.36 | 58.00 | 1.88 Bn |
| 256 | PHVS | Pharvaris N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | -24.17 | — | 1.77 Bn |
| 257 | ZBIO | Zenas BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -4.98 | 2,069.45 | 2.07 Bn |
| 258 | XNCR | Xencor Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.02 Bn | -12.34 | 19.20 | 1.64 Bn |
| 259 | AGIO | Agios Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.98 Bn | -4.82 | 20.16 | 1.98 Bn |
| 260 | STOK | Stoke Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | -9.48 | 71.43 | 1.68 Bn |
| 261 | RXRX | Recursion Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.95 Bn | -3.75 | 35.48 | 1.40 Bn |
| 262 | VIR | Vir Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | -7.64 | 6.34 | 1.92 Bn |
| 263 | INBX | Inhibrx Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.91 Bn | -14.29 | 1,466.08 | 1.91 Bn |
| 264 | IMCR | Immunocore Holdings plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | -103.98 | 4.37 | 1.00 Bn |
| 265 | LKFT | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | 0.01 | 1.63 | 1.88 Bn |
| 266 | TYRA | Tyra Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.88 Bn | -12.66 | — | 1.88 Bn |
| 267 | SNDX | Syndax Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.85 Bn | -10.19 | 7.33 | 1.30 Bn |
| 268 | SCNI | Scinai Immunotherapeutics Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.78 Bn | -211.92 | 1,030.81 | 1.77 Bn |
| 269 | CMPS | COMPASS Pathways plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | -4.49 | — | 1.77 Bn |
| 270 | DMRA | Damora Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.70 Bn | -6.48 | — | 1.16 Bn |
| 271 | GHRS | GH Research PLC | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.69 Bn | -27.13 | — | 1.33 Bn |
| 272 | NVAX | Novavax Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.69 Bn | -6.81 | 4.08 | 0.97 Bn |
| 273 | SEPN | Septerna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.66 Bn | -119.04 | 16.81 | 1.66 Bn |
| 274 | ANAB | Anaptysbio, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.64 Bn | -68.50 | 8.21 | 1.35 Bn |
| 275 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.61 Bn | -3.49 | 2.25 | 1.32 Bn |
| 276 | ATAI | AtaiBeckley Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.59 Bn | -10.36 | 525.18 | 1.59 Bn |
| 277 | BCAX | Bicara Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -8.53 | — | 1.58 Bn |
| 278 | FBRX | Forte Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 279 | AAPG | Ascentage Pharma Group International | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.57 Bn | -9.11 | 20.12 | 1.29 Bn |
| 280 | MAZE | Maze Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | -14.62 | 77.55 | 1.55 Bn |
| 281 | ANRO | Alto Neuroscience, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.53 Bn | -18.21 | — | 1.53 Bn |
| 282 | ANIP | Ani Pharmaceuticals Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 1.51 Bn | 14.01 | 1.55 | 1.15 Bn |
| 283 | SDGR | Schrodinger, Inc. | secondary | T-27 | Vertical Software | TG-05 | 1.50 Bn | -27.68 | 5.81 | 1.09 Bn |
| 284 | AVBP | ArriVent BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -8.94 | — | 1.46 Bn |
| 285 | REPL | Replimune Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.46 Bn | -4.90 | — | 1.46 Bn |
| 286 | ALMS | Alumis Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.44 Bn | -5.95 | 173.22 | 0.94 Bn |
| 287 | GLUE | Monte Rosa Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.43 Bn | -9.31 | 49.91 | 0.80 Bn |
| 288 | ABSI | Absci Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -11.66 | 904.38 | 1.21 Bn |
| 289 | ORIC | Oric Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | -8.79 | — | 1.38 Bn |
| 290 | OMER | Omeros Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.38 Bn | 80.89 | 35.93 | 1.38 Bn |
| 291 | CGEM | Cullinan Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -6.71 | — | 1.37 Bn |
| 292 | SVRA | Savara Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.35 Bn | -9.72 | — | 1.35 Bn |
| 293 | VOR | Vor Biopharma Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.34 Bn | -1.46 | — | 1.34 Bn |
| 294 | CRVS | Corvus Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.34 Bn | -28.01 | — | 1.12 Bn |
| 295 | JANX | Janux Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -12.32 | 52.66 | 1.26 Bn |
| 296 | MNKD | Mannkind Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.26 Bn | -28.82 | 3.19 | 1.14 Bn |
| 297 | JBIO | Jade Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.22 Bn | -7.94 | — | 1.22 Bn |
| 298 | CLYM | Climb Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.20 Bn | -20.81 | — | 1.20 Bn |
| 299 | IMTX | Immatics N.V. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.14 Bn | -4.75 | 23.55 | 0.69 Bn |
| 300 | MLTX | MoonLake Immunotherapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.10 Bn | -4.16 | — | 0.57 Bn |